Co-Authors
This is a "connection" page, showing publications co-authored by VIVEK SUBBIAH and GREGORY RAVIZZINI.
Connection Strength
1.650
-
Phase I Study of P-cadherin-targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors. Clin Cancer Res. 2020 11 15; 26(22):5830-5842.
Score: 0.741
-
Dosimetry of a Novel 111Indium-Labeled Anti-P-Cadherin Monoclonal Antibody (FF-21101) in Non-Human Primates. Cancers (Basel). 2023 Sep 13; 15(18).
Score: 0.229
-
18F-sodium fluoride positron emission tomography (NaF-18-PET/CT) radiomic signatures to evaluate responses to alpha-particle Radium-223 dichloride therapy in osteosarcoma metastases. Curr Probl Cancer. 2021 10; 45(5):100797.
Score: 0.200
-
Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST. ESMO Open. 2019; 4(1):e000439.
Score: 0.167
-
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clin Cancer Res. 2019 07 01; 25(13):3802-3810.
Score: 0.167
-
An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3'-deoxy-3'[(18)F]-Fluorothymidine Positron Emission Tomography 18F-FLT PET/CT in Prostate Adenocarcinoma. Diagnostics (Basel). 2017 Apr 04; 7(2).
Score: 0.147